Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Galapagos NV ADR (GLPG)

Galapagos NV ADR (GLPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,013,812
  • Shares Outstanding, K 65,897
  • Annual Sales, $ 259,450 K
  • Annual Income, $ 229,120 K
  • 60-Month Beta 0.23
  • Price/Sales 7.79
  • Price/Cash Flow 46.32
  • Price/Book 0.63
Trade GLPG with:

Options Overview Details

View History
  • Implied Volatility 16.51% ( -14.08%)
  • Historical Volatility 39.46%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 80.76% on 07/18/24
  • IV Low 16.51% on 09/18/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 125
  • Volume Avg (30-Day) 343
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 6,813
  • Open Int (30-Day) 4,939

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate 0.04
  • Low Estimate -0.35
  • Prior Year 0.09
  • Growth Rate Est. (year over year) -277.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.45 +23.84%
on 08/19/24
30.91 -2.04%
on 09/17/24
+5.84 (+23.90%)
since 08/16/24
3-Month
24.16 +25.33%
on 08/14/24
30.91 -2.04%
on 09/17/24
+4.44 (+17.18%)
since 06/18/24
52-Week
24.16 +25.33%
on 08/14/24
42.46 -28.68%
on 01/08/24
-5.67 (-15.77%)
since 09/18/23

Most Recent Stories

More News
+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients

/PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as...

GLPG : 30.28 (-0.92%)
Why Galapagos Trounced the Market Today

A high-profile healthcare industry executive has been tapped as the company's new CEO.

GLPG : 30.28 (-0.92%)
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF

Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat...

GLPG : 30.28 (-0.92%)
GILD : 83.89 (+1.01%)
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development...

GLPG : 30.28 (-0.92%)
GILD : 83.89 (+1.01%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV (“Galapagos” or the “Company”) (NASDAQ: GLPG).   Such investors are...

GLPG : 30.28 (-0.92%)
Global UV Disinfection Equipment Market Could Exceed $5 Billion By 2025

Palm Beach, FL – November 5, 2020 – During the present global pandemic, certain industries have actually grown… the global UV disinfection market is one of those industries. New product manufacturing...

GLPG : 30.28 (-0.92%)
AUVI : 0.2926 (-8.56%)
JNJ : 166.15 (-0.55%)
NVAX : 12.56 (-2.86%)
GILD : 83.89 (+1.01%)
GSK : 42.43 (-0.31%)
VIR : 7.80 (-1.64%)
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the application for a new indication to the approved license for filgotinib 200 mg, an oral JAK1 preferential...

GLPG : 30.28 (-0.92%)
GILD : 83.89 (+1.01%)
Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral,...

GILD : 83.89 (+1.01%)
GLPG : 30.28 (-0.92%)
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca ® (filgotinib 200 mg...

GILD : 83.89 (+1.01%)
GLPG : 30.28 (-0.92%)
Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory...

GILD : 83.89 (+1.01%)
GLPG : 30.28 (-0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include...

See More

Key Turning Points

3rd Resistance Point 31.04
2nd Resistance Point 30.87
1st Resistance Point 30.58
Last Price 30.28
1st Support Level 30.12
2nd Support Level 29.95
3rd Support Level 29.66

See More

52-Week High 42.46
Fibonacci 61.8% 35.47
Fibonacci 50% 33.31
Fibonacci 38.2% 31.15
Last Price 30.28
52-Week Low 24.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar